Prolonged signal-averaged P wave duration as a prognostic marker for morbidity and mortality in patients with congestive heart failure

Scandinavian Cardiovascular Journal

Volumn 37, Issue 4, 2003, Pages 193-198

  Dixen, Ulrik ^a   Wallevik, Laura ^a   Hansen, Maja S ^a   Haghfelt, Anne ^a   Aqraou, Katja F ^a   Abildstrom, Steen Z ^b   Frandsen, Erik ^b   Jensen, Gorm B ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Congestive heart failure; P wave; Prognostic marker; Signal average

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; POTASSIUM SPARING DIURETIC AGENT; WARFARIN;

ADULT; AGE; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; DEATH; DETERIORATION; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HAZARD ASSESSMENT; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HOSPITALIZATION; HUMAN; MALE; MEDICAL ASSESSMENT; MEDICAL DOCUMENTATION; MORBIDITY; MORTALITY; P WAVE; PATIENT INFORMATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; SIGNAL AVERAGED ELECTROCARDIOGRAPHY; TIME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CALCIUM CHANNEL BLOCKERS; DIGOXIN; ELECTROCARDIOGRAPHY, AMBULATORY; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; MALE; MIDDLE AGED; MORBIDITY; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PROGNOSIS; RISK FACTORS; STATISTICS, NONPARAMETRIC; STROKE VOLUME; TREATMENT OUTCOME;

EID: 0042380174     PISSN: 14017431     EISSN: None     Source Type: Journal    
DOI: 10.1080/14017430310002202     Document Type: Article

References (23)

1. Ryden-Bergsten T, Andersson F. The health care costs of heart failure in Sweden. J Intern Med 1999; 246: 275-284.
2. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: Trends in incidence and survival in a 10-year period. Arch Intern Med 1999; 159: 29-34.
3. Zannad F, Braincon S, Juilliere Y, et al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: The EPICAL Study. Epidemiologie de l'Insuffisance Cardiaque Avancee en Lorraine. J Am Coll Cardiol 1999; 33: 734-742.
4. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996; 78: 902-907.
5. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-H): A randomised trial. Lancet 1999; 353: 9-13.
6. Goldstein S, Hjalmarson A. The mortality effect of metoprolol CR/XL in patients with heart failure: Results of the MERIT-HF Trial. Clin Cardiol 1999; 22 Suppl 5: V30-V35.
7. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333: 1670-1676.
8. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13.
9. McDonagh TA, Cunningham AD, Morrison CE, et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 2001; 86: 21-26.
10. Nielsen OW, Hilden J, Hansen JF. Strong prognostic value of combining N-terminal atrial natriuretic peptide and ECG to predict death in heart patients from general practice. Heart 2001; 86: 218-219.
11. Guidera SA, Steinberg JS. The signal-averaged P wave duration: A rapid and noninvasive marker of risk of atrial fibrillation. J Am Coll Cardiol 1993; 21: 1645-1651.
12. Montereggi A, Marconi P, Olivotto I, et al. Signal-averaged P-wave duration and risk of paroxysmal atrial fibrillation in hyperthyroidism. Am J Cardiol 1996; 77: 266-269.
13. Steinberg JS, Zelenkofske S, Wong SC, et al. Value of the P-wave signal-averaged ECG for predicting atrial fibrillation after cardiac surgery. Circulation 1993; 88: 2618-2622.
14. Yamada T, Fukunami M, Shimonagata T, et al. Prediction of paroxysmal atrial fibrillation in patients with congestive heart failure: A prospective study. J Am Coll Cardiol 2000; 35: 405-413.
15. Crijns HJ, Tjeerdsma G, de Kam PJ, et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J 2000; 21: 1238-1245.
16. Stevenson WG, Stevenson LW, Middlekauff HR, et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 1996; 28: 1458-1463.
17. Petersen P, Godtfredsen J. Risk factors for stroke in chronic atrial fibrillation. Eur Heart J 1988; 9: 291-294.
18. Faggiano P, D'Aloia A, Zanelli E, et al. Contribution of left atrial pressure and dimension to signal-averaged P-wave duration in patients with chronic congestive heart failure. Am J Cardiol 1997; 79: 219-222.
19. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001; 141: 367-374.
20. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: Analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002; 106: 416-422.
21. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-1130.
22. Nishino M, Hoshida S, Tanouchi J, et al. Time to recover from atrial hormonal, mechanical, and electrical dysfunction after successful electrical cardioversion of persistent atrial fibrillation. Am J Cardiol 2000; 85: 1451-1454.
23. Wijbenga AA, Balk AH, Jonkman FA, et al. Relation of atrial natriuretic peptides to left ventricular systolic and diastolic function in heart failure. Eur J Heart Fail 1999; 1: 51-58.